RTP Mobile Logo

Interview with S Vincent Rajkumar, MD

Track 1: Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM
Track 2: Subcutaneous versus intravenous daratumumab administration for MM
Track 3: Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT)
Track 4: Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM
Track 5: Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT
Track 6: Case: A man in his early 80s with MM initially treated with lenalidomide/bortezomib/dexamethasone and maintenance lenalidomide experiences relapse 2 years later
Track 7: Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial
Track 8: Proposed mechanism of venetoclax-associated mortality in MM
Track 9: Understanding the clinical role and limitations of surrogate endpoints for overall survival
Track 10: Perspective on the design of the BELLINI trial

Interview with Paul G Richardson, MD

Track 1: Approach to treatment decision-making for patients with newly diagnosed MM; strategic use of transplant and evolution of treatment modalities
Track 2: Case: A woman in her early 70s presents with lambda light chain MM and widespread lytic bone disease
Track 3: Consideration of daratumumab as a component of induction therapy
Track 4: Comparison of the efficacy, tolerability and dosing of bortezomib and ixazomib in the up-front setting
Track 5: Activity and tolerability of melflufen in combination with dexamethasone in patients with R/R MM refractory to pomalidomide and/or daratumumab
Track 6: Novel mechanism of action of melflufen; synergistic activity in combination with dexamethasone and either bortezomib or daratumumab on the ANCHOR trial
Track 7: Clinical experience with melflufen-associated cytopenias
Track 8: Mechanism of action, activity, tolerability and recent FDA approval of the XPO1 inhibitor selinexor in combination with dexamethasone for multiagent-refractory MM
Track 9: Case: A man in his late 50s with R/R MM receives anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy on a clinical trial
Track 10: Therapeutic options after disease progression on anti-BCMA CAR T-cell therapy
Track 11: Frequency and severity of toxicities, including cytokine release syndrome, observed with various BCMA-directed CAR T-cell platforms
Track 12: Case: A man in his early 60s with R/R MM with the t(11;14) translocation elects to hold ASCT “in reserve” and receives carfilzomib/venetoclax
Track 13: BELLINI trial: Perspective on outcomes for patients with and without t(11;14)

Interview with Nina Shah, MD

Track 1: Recently approved and novel antibodies in the treatment of MM
Track 2: Use and tolerability of elotuzumab/pomalidomide/dexamethasone for patients with R/R MM
Track 3: Activity, tolerability and ongoing investigation of the anti-CD38 antibodies daratumumab and isatuximab
Track 4: Biologic rationale for targeting BCMA; near universal expression of BCMA on MM cells
Track 5: Exploration of consolidation anti-BCMA CAR T-cell therapy after transplant
Track 6: Outcomes and frequency and severity of toxicities observed with BCMA-directed CAR T-cell platforms versus those targeting CD19
Track 7: Case: A man in his early 60s with R/R MM receives anti-BCMA CAR T-cell therapy on a clinical trial
Track 8: Clinical manifestations and management of cytokine release syndrome associated with anti-BCMA CAR T-cell therapy
Track 9: Correlation between toxicity and benefit with BCMA-directed CAR T-cell therapy
Track 10: Challenges to entering patients on CAR T-cell therapy trials
Track 11: DREAMM-1 trial: Efficacy and safety of the investigational BCMA-directed antibody-drug conjugate GSK2857916 in patients with heavily pretreated MM
Track 12: Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety of AMG 420
Track 13: Case: A man in his early 80s with newly diagnosed MM receives CyBorD (cyclophosphamide/bortezomib/dexamethasone) followed by maintenance lenalidomide
Track 14: Phase III MAIA trial: Efficacy and tolerability of lenalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT

Interview with Irene M Ghobrial, MD

Track 1: Case: A woman in her late 60s with high-risk R/R MM attains an excellent response to daratumumab/pomalidomide/dexamethasone
Track 2: Evidence-based selection of up-front treatment combinations for younger versus older patients with newly diagnosed MM
Track 3: Clinical significance of minimal residual disease (MRD) assessment; correlation between MRD negativity and long-term outcomes for patients with newly diagnosed MM receiving treatment
Track 4: Selection, use and duration of maintenance therapy after ASCT
Track 5: Significance of CHIP (clonal hematopoiesis of indeterminate potential) mutations and increased predisposition to hematologic cancer or cardiovascular-associated mortality
Track 6: Therapeutic options for patients who experience disease progression on maintenance lenalidomide
Track 7: Mechanisms of action of elotuzumab and daratumumab; activity and safety of immune-directed therapies for MM
Track 8: Response and tolerability of anti-BCMA CAR T-cell therapies
Track 9: Case: A man in his mid-50s with multiagent-refractory MM receives a BCMA-directed antibody-drug conjugate on a clinical trial
Track 10: Case: A woman in her early 40s with high-risk smoldering MM with deletion 17p experiences a partial response to elotuzumab/lenalidomide/dexamethasone
Track 11: Efficacy and cardiotoxicity with second-line carfilzomib/lenalidomide/dexamethasone followed by maintenance carfilzomib/lenalidomide for del(17p) smoldering MM
Track 12: Activity of melflufen in patients with heavily pretreated MM
Track 13: Newly approved and investigational approaches for heavily pretreated MM
Track 14: Incidence of BRAF mutations in patients with MM; activity and ongoing investigation of BRAF inhibitors for R/R MM
S Vincent Rajkumar, MD
Edward W and Betty Knight
Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California
Irene M Ghobrial, MD
Professor of Medicine
Clinical Investigator Research Program
Michele and Stephen Kirsch Laboratory
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida